Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples
O'Brien O, Gray S, Jörger M, Jochum W, Fabre A, Cuffe S, Nicholson S, Leonard N, Geoghegan O, O'Brien C, Wright M, Finn S. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. Diagnostics (Basel) 2019; 9
Jan 18, 2019Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples
Jan 18, 2019Diagnostics (Basel) 2019; 9
O'Brien Odharnaith, Gray Steven G, Jörger Markus, Jochum Wolfram, Fabre Aurelie, Cuffe Sinead, Nicholson Siobhan, Leonard Niamh, Geoghegan Orla, O'Brien Cathal, Wright Mark C, Finn Stephen P
Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer
Überall I, Gachechiladze M, Jörger M, Anděl J, Smičková P, Kolek V, Grygárková I, Škarda J. Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer. Lung Cancer 2019; 129:85-91.
Jan 8, 2019Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer
Jan 8, 2019Lung Cancer 2019; 129:85-91
Überall Ivo, Gachechiladze Mariam, Jörger Markus, Anděl Josef, Smičková Petra, Kolek Vítězslav, Grygárková Ivona, Škarda Josef
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Crombag M, Beijnen J, Mathijssen R, van Erp N, Dorlo T, Schellens J, Jörger M, Wijngaard S, Koolen S, de Vries Schultink A, Huitema A. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharm Res 2019; 36:33.
Jan 7, 2019Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Jan 7, 2019Pharm Res 2019; 36:33
Crombag Marie-Rose B S, Beijnen Jos H, Mathijssen Ron H J, van Erp Nielka P, Dorlo Thomas P C, Schellens Jan H M, Jörger Markus, Wijngaard Sophie, Koolen Stijn L W, de Vries Schultink Aurelia H M, Huitema Alwin D R
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer
Siano M, Espeli V, Jörger M. Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer. Tumori 2018:300891618811276.
Nov 26, 2018Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer
Nov 26, 2018Tumori 2018:300891618811276
Siano Marco, Espeli Vittoria, Jörger Markus
Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study
Behrend H, Lengnick H, Zdravkovic V, Ladurner A, Rudin D, Erschbamer M, Jörger M, Kuster M. Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study. Knee Surg Sports Traumatol Arthrosc 2018
Jun 28, 2018Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study
Jun 28, 2018Knee Surg Sports Traumatol Arthrosc 2018
Behrend Henrik, Lengnick Harald, Zdravkovic Vilijam, Ladurner Andreas, Rudin Diana, Erschbamer Matthias, Jörger Markus, Kuster Markus
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy
Beumer J, Boku N, Muneoka K, Arnold D, Zhang L, Mathijssen R, Kim T, Diasio R, Milano G, Tanigawara Y, Allegra C, Chu E, Jörger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 2018
Jun 20, 2018Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy
Jun 20, 2018Clin Pharmacol Ther 2018
Beumer Jan H, Boku Narikazu, Muneoka Katsuki, Arnold Dirk, Zhang Li, Mathijssen Ron H, Kim Tae Won, Diasio Robert, Milano Gerard, Tanigawara Yusuke, Allegra Carmen, Chu Edward, Jörger Markus
Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer
Siano M, Jarisch N, Jörger M, Espeli V. Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. Anticancer Res 2018; 38:3725-3729.
Jun 1, 2018Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer
Jun 1, 2018Anticancer Res 2018; 38:3725-3729
Siano Marco, Jarisch Nadine, Jörger Markus, Espeli Vittoria
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
Apr 13, 2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Apr 13, 2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Neven P, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé V, Van Calster B, Jörger M, Verhoeven D, Berteloot P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné A, Brouckaert O, Decloedt J, Guchelaar H. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clin Cancer Res 2018; 24:2312-2318.
Feb 19, 2018Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Feb 19, 2018Clin Cancer Res 2018; 24:2312-2318
Neven Patrick, Vuylsteke Peter, Wynendaele Wim, Casteels Minne, Van Huffel Sabine, Lybaert Willem, Van Ginderachter Johan, Paridaens Robert, Vergote Ignace, Dezentjé Vincent Olaf, Van Calster Ben, Jörger Markus, Verhoeven Didier, Berteloot Patrick, Jongen Lynn, Lintermans Anneleen, Van Asten Kathleen, Blomme Chantal, Lambrechts Diether, Poppe An, Wildiers Hans, Dieudonné Anne-Sophie, Brouckaert Olivier, Decloedt Jan, Guchelaar Henk-Jan
Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients
Klopp-Schulze L, Jörger M, Wicha S, Ter Heine R, Csajka C, Parra-Guillen Z, Kloft C. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clin Pharmacokinet 2018; 57:229-242.
Feb 1, 2018Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients
Feb 1, 2018Clin Pharmacokinet 2018; 57:229-242
Klopp-Schulze Lena, Jörger Markus, Wicha Sebastian G, Ter Heine Rob, Csajka Chantal, Parra-Guillen Zinnia P, Kloft Charlotte
Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
Jörger M, Miller M, Baburina I, Jog S, Cline D, Courtney J, Hilger R, Jaehde U, Kraff S, Salamone S. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit 2017; 39:617-624.
Dec 1, 2017Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
Dec 1, 2017Ther Drug Monit 2017; 39:617-624
Jörger Markus, Miller M Craig, Baburina Irina, Jog Sonali, Cline Daniel J, Courtney Jodi B, Hilger Ralf A, Jaehde Ulrich, Kraff Stefanie, Salamone Salvatore J
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
Jun 19, 2017Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Jun 19, 2017Basic Clin Pharmacol Toxicol 2017; 121:309-315
Parra-Guillen Zinnia P, Kloft Charlotte, Krähenbühl Stephan, Gillessen Sommer Silke, Früh Martin, Pfister Bogumila, Winogradova Daria, Donzelli Massimiliano, Haschke Manuel, Berger Peter B, Jörger Markus
Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Henrich A, Jörger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362:347-358.
Jun 9, 2017Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Jun 9, 2017J Pharmacol Exp Ther 2017; 362:347-358
Henrich Andrea, Jörger Markus, Kraff Stefanie, Jaehde Ulrich, Huisinga Wilhelm, Kloft Charlotte, Parra-Guillen Zinnia Patricia
Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity
Hamzic S, Kummer D, Milesi S, Mueller D, Jörger M, Aebi S, Amstutz U, Largiader C. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017; 102:796-804.
May 30, 2017Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity
May 30, 2017Clin Pharmacol Ther 2017; 102:796-804
Hamzic S, Kummer D, Milesi S, Mueller D, Jörger Markus, Aebi S, Amstutz U, Largiader C R
RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
Gachechiladze M, Škarda J, Soltermann A, Jörger M. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. Int J Cancer 2017; 141:1286-1294.
May 19, 2017RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
May 19, 2017Int J Cancer 2017; 141:1286-1294
Gachechiladze Mariam, Škarda Josef, Soltermann Alex, Jörger Markus
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Baty F, Jörger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
Mar 30, 201724h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Mar 30, 2017J Transl Med 2017; 15:66
Baty Florent, Jörger Markus, Früh Martin, Klingbiel Dirk, Zappa Francesco, Brutsche Martin
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C, Allegrini S, Ackermann C, Mark M, Jörger M, Griguolo G, Homicsko K, von Moos R, Hess D, Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
Mar 20, 2017Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Mar 20, 2017Invest New Drugs 2017; 35:766-772
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C V, Allegrini S, Ackermann C J, Mark M, Jörger Markus, Griguolo G, Homicsko K, von Moos R, Hess Dagmar, Swiss Group for Clinical Cancer Research (SAKK)
Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárková I, Kolek V, Škarda J, Jörger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer 2017; 105:31-38.
Jan 18, 2017Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Jan 18, 2017Lung Cancer 2017; 105:31-38
Gachechiladze Mariam, Soltermann Alex, Weder Walter, Stahel Rolf, Baty Florent, Kolář Zdeněk, Bouchal Jan, Langová Kateřina, Grygárková Ivona, Kolek Vítězslav, Škarda Josef, Jörger Markus
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies
Meulendijks D, Rozeman E, Cats A, Sikorska K, Jörger M, Deenen M, Beijnen J, Schellens J. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J 2016
Dec 20, 2016Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies
Dec 20, 2016Pharmacogenomics J 2016
Meulendijks D, Rozeman E A, Cats A, Sikorska K, Jörger Markus, Deenen M J, Beijnen J H, Schellens J H M